Advanced search
Publication Cover
Drug, Healthcare and Patient Safety Volume 6, 2014 - Issue
Submit an article Journal homepage
64
Views
6
CrossRef citations to date
0
Altmetric
Short Report

Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems

Jan Schjøtt1 Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway;2 Institute of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway;3 Regional Medicines Information and Pharmacovigilance Centre (RELIS Vest), Haukeland University Hospital, Bergen, NorwayCorrespondence[email protected]
&
Jenny Bergman3 Regional Medicines Information and Pharmacovigilance Centre (RELIS Vest), Haukeland University Hospital, Bergen, Norway
Pages 89-92 | Published online: 01 Jul 2014

References

  • Uppsala Monitoring CentreSafety Monitoring of Medicinal Products: Guidelines for Setting up and Running a Pharmacovigilance CentreUppsalaUppsala Monitoring Centre2000
  • ArimoneYBidaultIDutertreJPUpdating the French method for the causality assessment of adverse drug reactionsTherapie2013682697623773347
  • OosterhuisIvan HunselFPvan PuijenbroekEPExpectations for feedback in adverse drug reporting by healthcare professionals in the NetherlandsDrug Saf201235322123222201474
  • SchjøttJPompEGedde-DahlAQuality and impact of problem-oriented drug information: a method to change clinical practice among physicians?Eur J Clin Pharmacol2002571289790211936710
  • SchjøttJ1ReppeLARolandPDWestergrenTA question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive studyBMJ Open201222e000642
  • [No authors listed]Gabapentin and pregabalin: abuse and addictionPrescrire Int20122112815215422822593
  • GrosshansMLemenagerTVollmertCPregabalin abuse among opiate addicted patientsEur J Clin Pharmacol201369122021202523989299
  • SchifanoFD’OffiziSPiccioneMIs there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam dataPsychother Psychosom201180211812221212719
  • BodénRWettermarkBBrandtLKielerHFactors associated with pregabalin dispensing at higher than the approved maximum doseEur J Clin Pharmacol201470219720424141597
  • TothCDrug safety evaluation of pregabalinExpert Opin Drug Saf201211348750222468635
  • HärmarkLvan PuijenbroekEStrausSvan GrootheestKIntensive monitoring of pregabalin: results from an observational, web-based, prospective cohort study in the Netherlands using patients as a source of informationDrug Saf201134322123121332246
  • WestinAABramnessJGChalabianlooFRygnestadTSlørdalLPregabalin should be moved to the prescription group BTidsskr Nor Laegeforen20131336615616 Norwegian23552152
  • BergsholmPPrescription group C correct for pregabalinTidsskr Nor Laegeforen20131331010441045 Norwegian23712140
  • Norwegian Pharmacovigilance Advisory BoardMinutes of meeting of December 11, 2013 Available from: www.legemiddelverket.no/Bivirkninger/bivirkningsnemnda/referater/Sider/default.aspxAccessed April 30, 2014
  • KarimiGStarKNorénGNHäggSThe impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilancePLoS One201387e6893823869234

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.